Interpace Biosciences™
Bringing Insights to Life

CHARTER OF THE REGULATORY COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS OF INTERPACE BIOSCIENCES, INC.

Purpose of the Committee

As a laboratory testing and service company in the clinical diagnostic and biopharma markets, Interpace Biosciences, Inc., ("we", "our", "us", "Interpace", or "the Company") is subject to a regulatory framework of laws and regulations with respect to its operations (the "Regulatory Framework"). The Regulatory Framework includes but is not limited to the operation and licensing of clinical laboratories, restrictions on the marketing of the Company's services, anti-bribery, anti-corruption and self-referral rules, and reimbursement and payment for the Company's services, including Medicare reimbursement. In addition, in providing services and performing tests and clinical studies, the Company must act in compliance with high quality, ethical and legal standards, and to be compliant with applicable operational, health, safety, quality, and regulatory requirements and best practices (collectively, "Standards").

The Regulatory Compliance Committee (the "Committee") is appointed by the Board of Directors (the "Board") of the Company to assist the Board in carrying out its oversight responsibility with respect to both the Regulatory Framework and the Standards and related issues and attendant risks and to oversee management's efforts to adopt and implement policies and procedures that require the Company and its employees to comply with the Regulatory Framework and the Standards. In particular the Committee shall assist the Board with respect to compliance with the operation of clinical laboratories and the provision of laboratory services, and related customer billing and Medicare reimbursement, as described in this Charter or as otherwise directed by the Board.

Membership of the Committee

1. The Committee shall be comprised of not less than three members of the Board.

2. At least a majority of the members of the Committee shall be independent directors, as independence is defined in accordance with the rules, regulations and standards of the Nasdaq Stock Market LLC ("Nasdaq"), as determined in the business judgment of the Board.

3. The members of the Committee shall be elected annually to one-year terms by majority vote of the non-employee directors of the Board at the first meeting of the Board following the annual meeting of stockholders. Any vacancy on the Committee shall be filled by majority vote of the Board at the next meeting of the

Board following the occurrence of the vacancy. No member of the Committee shall be removed except by majority vote of the non-employee directors of the Board.

4. Members of the Committee shall be informed, or shall become informed, within a reasonable period of time after appointment to the Committee, with respect to matters of legal, regulatory and quality compliance that are within the Committee's oversight responsibilities.

Committee Chairman

The Board shall designate one member of the Committee to act as the Chairperson of the Committee after considering the recommendation of the Nominating & Corporate Governance Committee. The Committee member so designated shall (a) chair all meetings of the Committee; and (b) perform such other activities as from time to time are requested by the other Committee members or as circumstances indicate.

Meetings of the Committee

1. The Committee shall meet once every fiscal quarter or more frequently as it shall determine is necessary to carry out its duties and responsibilities.

2. The Committee will hold separate private meetings at least semi-annually with each of the Compliance Officer, the Director of Quality and Compliance, the Chief Medical Officer and the Chief Commercial Officer.

Duties and Responsibilities

Management is responsible for the Company's compliance with the Regulatory Framework and the Standards. The Committee is responsible for oversight of management's performance of these responsibilities. In carrying out its oversight responsibilities, the Committee is not providing any expert or special assurance as to the Company's regulatory or legal compliance. Moreover, the Committee does not have oversight of areas of financial compliance, which are the responsibility of the Audit Committee.

In carrying out its oversight responsibilities, the Committee shall perform the following functions:

1. **Healthcare Compliance:** Review and discuss with management the implementation and enforcement of policies, standards, procedures, and training and risk management programs, and compliance with the Regulatory Framework and the Standards, in the areas of healthcare compliance and anti- corruption, including without limitation with respect to the operation of clinical laboratories and the provision of laboratory services, related customer billing and Medicare reimbursement and reimbursement with respect to other government programs and private insurance, and healthcare, patient privacy and data security laws and regulations, including the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and the Health Information Technology for Economic and

Clinical Health Act ("HITECH"), regulations promulgated thereunder, and corresponding statutes and regulations implemented by states and foreign jurisdictions.

In furtherance of this responsibility:

- At least quarterly, the Compliance Officer and the Head of Compliance shall discuss with the Committee specific substantive critical healthcare compliance risks and issues (including HIPAA, customer billing and Medicare reimbursement, and compliance investigations), as well as trends in healthcare compliance, and the Company's plans to address them.
- At least quarterly, the Compliance Officer shall discuss with the Committee the results of any regulatory compliance program auditing and monitoring.
- At least annually, the Committee shall review with the Compliance Officer (i) the implementation and effectiveness of the Company's healthcare compliance programs (including training), (ii) the adequacy of the resources for those programs, (iii) organizational talent and process improvements and (iv) the healthcare compliance programs of newly acquired companies.
- The Committee shall review and discuss with management the implementation and enforcement of policies, standards, procedures and risk management programs, and compliance with applicable laws and regulations, related to the U.S. Foreign Corrupt Practices Act ("FCPA") and other anti-corruption laws.
- The Committee shall review and discuss with management the results of any inspections or other regulatory actions and any significant deviations observed by the Company's quality functions.

2. **Other Areas of Regulatory Compliance:** At least annually, the Committee shall review and discuss with relevant management the implementation and effectiveness of regulatory risk management programs in the areas listed below. These annual reviews for each such area should focus on specific substantive critical regulatory compliance issues, regulatory risk management issues, and trends in regulatory enforcement and compliance and how the Company plans to address them.

- Supply Chain
- Environmental regulations
- Employee health and safety
- Privacy
- Cybersecurity
- Political expenditures and lobbying activities

3. **Other Reports Received.** The Committee shall review and address any reports or other information related to the Regulatory Framework or the Standards and received through the Company's ethics hotline or otherwise received from management or an employee or consultant of the Company, including those received not in the ordinary course from the Compliance Officer, the Head of Compliance or the Chief Commercial Officer. Such reports include but are not limited to notices of complaints and allegations relating to the Company's operations that are deemed to be material by the Chairperson of the Committee or the Compliance Officer, the Head of Compliance or the Chief Commercial Officer.

4. **Government Agreements:** The Committee shall receive and review updates on compliance with any ongoing Corporate Integrity Agreements or similar significant undertakings by the Company with the U.S. Department of Health and Human Services, U.S. Department of Justice, U.S. Securities and Exchange Commission, U.S. Food and Drug Administration, or any other government agency.

5. Maintain procedures, as set forth in Annex A hereto, for the receipt, retention and treatment of complaints received by the Company regarding questionable corporate, regulatory or related matters.

Oversight of Committee Matters

1. The Committee shall report regularly to the Board on its meetings and discussions and review with the Board significant issues or concerns that arise at Committee meetings.

2. The Committee shall maintain written minutes of its meetings.

3. The Chairperson or any one or more members of the Committee, as designated by the Committee, may act on behalf of the Committee.

4. The Committee may form and delegate authority to subcommittees when appropriate.

5. The Committee shall have authority and appropriate funds to retain, consult with and compensate outside counsel, consultants, regulatory experts and other advisors as the Committee may deem appropriate.

6. The Committee shall conduct an annual evaluation of its performance in fulfilling its duties and responsibilities under this Charter and shall assess the adequacy of the reporting and information provided by management to support the Committee's oversight responsibilities.

7. The Committee shall, on an annual basis, review and reassess the adequacy of this Charter and recommend any proposed changes to the Board for approval.

Adopted: July 9, 2020

Annex A

PROCEDURES FOR THE ANONYMOUS SUBMISSION OF COMPLAINTS OR CONCERNS REGARDING CORPORATE AND REGULATORY COMPLIANCE

The following is the procedure for the confidential, anonymous submission by employees of Interpace Biosciences, Inc. and its subsidiaries (the "Company") of concerns regarding questionable corporate, regulatory or related matters ("Concerns"):

1. The Company shall forward to the Regulatory Compliance Committee of the Board of Directors (the "Regulatory Committee") any complaints that it has received regarding Concerns.

2. Employees are expected to report any Concerns and may do so on a confidential, anonymous basis if the employee so desires, in either of the following manners: (i) by emailing such Concerns to compliance@interpace.com (ii) by reporting such Concerns via a confidential and secure Internet and telephone based reporting system administered by an external vendor (the "Compliance Hotline"), which may be accessed via the Intranet at https://intranet.interpacedx.com/whistleblower-contact/ or toll-free by telephone at 1-866-238-1324, or (iii) by setting forth such Concerns in writing and forwarding them in a sealed envelope to the Chair of the Regulatory Committee, in care of the Company's Corporate Secretary, at the following mailing address: Interpace Biosciences, Inc., Chair of the Regulatory Committee of the Board of Directors, c/o Corporate Secretary, Morris Corporate Center 1, Building C, 300 Interpace Parkway, Parsippany, NJ 07054. The sealed envelope should be labeled with a legend such as: "Anonymous Submission of Complaint or Concern." The Compliance Hotline toll free telephone number and website address as well as the mailing address for receiving complaints regarding Accounting Issues from employees and others have also been published on the Company's website: https://ir.interpace.com/governance-docs

   If an employee would like to discuss any matter with the Regulatory Committee, the employee should indicate this in the submission made via the Compliance Hotline or in writing and include a telephone number at which he or she might be contacted if the Regulatory Committee deems it appropriate. Any such requests received by the Company's Compliance or Human Resources department shall be forwarded promptly to the Chair of the Regulatory Committee.

   Reports will be treated confidentially to the extent reasonably possible given the need to conduct an investigation. The Company has established a Whistleblower Policy and no one will be subject to retaliation because of a good faith report of a complaint or concern regarding compliance issues. A copy of the Whistleblower Policy may be obtained on the Company's Intranet site under the documents section.

3. Regardless of whether a message is received on the Compliance Hotline through the telephone or internet, the Chair of Regulatory Committee or another person designated by him or her will review messages received on the Compliance Hotline and, within 48 business hours of receipt of e-mail notification, will arrange for the Committee to meet to discuss the report. Such messages shall be recorded on a confidential log maintained by the Company's independent Compliance Hotline vendor and shall contain at least the following data:

- date submitted;
- status;
- supervisor or management involvement;
- management's knowledge of the issue;
- general nature of this matter;
- name of reporter if identified

4. The Company shall prepare an executive summary of the contents of each with respect to Concerns and send it to the Chair of the Regulatory Committee. The Chair of the Regulatory Committee shall promptly investigate the subject of each such executive summary and report his or her findings in writing with recommendations, if any. The Chair of the Regulatory Committee will then communicate the complaint to other members of the Regulatory Committee. The Company's Compliance Officer shall send a copy of each submission with respect to Concerns that specifically allege participation in wrongdoing by the CEO to the Chair of the Regulatory Committee.

5. At least quarterly to coincide with each Regulatory Committee meeting, the Compliance Officer or designee will discuss all activity with the Chair of the Regulatory Committee.

6. The Regulatory Committee shall retain any such complaints or concerns for an appropriate period of time in accordance with legal requirements and any applicable document retention policies of the Company.

This Annex A shall appear on the Company's website as part of this Charter